- Price
- $6.82
- Day
- +6.73%
- Mkt Cap
- $388.71M
- 52W Range
- $4.00 – $7.54
- Volume
- 1.21M
- Beta
- 1.34
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Read full article
NEW YORK, July 27, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Abeona Therapeutics Inc. (NASDAQ: ABEO) on behalf of the company's shareholders. The investigation seeks to determine whether Abeona Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Read full article
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN ® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). “Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC.
Read full article